Miriam Merad

Last updated
Miriam Merad
Born
Paris, France
Education
Scientific career
Fields
Institutions Icahn School of Medicine at Mount Sinai

Miriam Merad (born 1969) [1] is an Algerian professor in Cancer immunology, Dean for Translational Research and Therapeutic Innovation, and Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology [2] and a member of the United States National Academy of Sciences [3] and the National Academy of Medicine. [4]

Contents

Education and career

Miriam Merad received her M.D. from the medical school at the University of Algiers in 1985 and completed her residency in hematology and oncology at the Paris Diderot University. [5] After obtaining a Master's degree in Biotechnology from the Paris Diderot University, she moved to Stanford University to perform a PhD in the laboratory of Edgar Engleman. [6] Merad’s clinical training in Hematology / Oncology and bone marrow transplantation in the Hôpital Saint-Louis and Institut Gustave Roussy in Paris shaped her initial interest in immunotherapy and inspired her move to Stanford to study dendritic cell-based vaccines with Engleman. Realizing that very little was known about myeloid cell development, Merad collaborated with Irving Weissman at Stanford on several studies that contributed to revisions in the understanding of macrophage and dendritic cell ontogeny. [7] She was recruited to ISMMS in 2004 and awarded an Endowed Chair in Cancer Immunology in 2014. [8]

In 2016, Merad was appointed Director of the Immunology Institute at ISMMS, which had been founded by Lloyd Mayer and Sergio A. Lira in 2007. The institute was renamed the Precision Immunology Institute (PrIISM) to reflect a focus on human immunology and translational research. PrIISM has co-founded several programs and centers with other institutes to support collaborations between physicians and scientists and synergy between fundamental, translational and clinical research initiatives. These include the Human Immune Monitoring Center, [9] the Microbiome Translational Center, [10] the Center for Inborn Errors of Immunity, [11] the TARGET and INTERACT programs [12] and the Center for Computational Immunology. [13]

In August 2023, Merad became the founding Chair of the Department of Immunology and Immunotherapy (DII), a new research department launched at ISMMS focusing on understanding the fundamental biology and impact of the immune system on human health and disease.

In April 2024, Merad was named the Dean for Translational Research and Therapeutic Innovation for the Icahn School of Medicine at Mount Sinai. [14]

Research

Miram Merad's early studies were among the first to identify the mechanisms that control the development and functional identity of tissue resident dendritic cells and macrophages. In particular, her laboratory established the embryonic origin of tissue resident macrophages, [15] microglia [16] and Langerhans cells [17] and investigates their distinct contributions to health and disease. These studies have revealed the critical contribution of tissue resident macrophages to organ physiology including synaptic pruning, gut peristaltism, fat metabolism and vascular integrity. The Merad laboratory identified a new subset of dendritic cells, the tissue resident CD103+ DC lineage, that are specialized in anti-viral and anti-tumor immunity.

Understanding how different myeloid cell subsets drive distinct inflammatory diseases is one focus of the Merad group's research. In 2021, they identified how mutations in mitogen-activated protein kinase pathway genes trigger sensescence in multipotent human hematopoietic progenitor cells that cause multisystem Langerhans Cell Histiocytosis disease by skewing progenitor differentiation towards the mononuclear phagocyte lineage. [18] In 2022, they reported that severe COVID19 disease was associated with a reduction in the tissue-resident lung alveolar macrophages that control tissue repair and an increase in inflammatory monocytes and monocyte-derived macrophages. [19]

The Merad lab has made many discoveries demonstrating the roles that dendritic cells and macrophages play within the tumor microenvironment. [1] The two distinct lineages of macrophages that Merad defined are represented in tumors, with the different developmental origins dictating their specific roles in shaping the tumor microenvironment. In human lung tumors, Merad's team found that tissue-resident macrophages gather near to tumour cells early in tumour formation and make the tumour cells more invasive, and they also activate a regulatory T cell response that protects the tumour cells from the immune system. [20] During tumor growth, the tissue-resident macrophages move to the periphery and monocyte-derived macrophages dominate the tumor-microenvironment. Other recent findings from the Merad team in this area include the identification of TREM2 tumor macrophages as immunosuppressive cells that limit natural killer cell recruitment and activity in a murine model of lung adenocarcinoma, [21] the characterization of mature dendritic cells enriched in immunoregulatory molecules (mregDCs) that limit responses to immune checkpoint blockade, [22] and the niches in tumors in which mregDCs operate. [23]

The Merad lab have reported how aging reshapes macrophages, shifting them from protective tissue guardians into drivers of disease, for example, by fueling cancer risk through immunosuppressive programs [24] and promoting neurodegeneration via senescent monocytes. Merad leads a semi-finalist team in the XPRIZE Healthspan competition, [25] testing strategies to reprogram these aging-linked immune cells for healthier longevity. [26]

In addition to her research program, Merad has published articles on new approaches to cancer immunotherapy clinical trials, [27] how Long COVID can be classified, [28] the importance of immigrants to science in the US [29] , written about her experiences as a mother and a scientist. [30] and founded in 2015 the International Immunoschool [31] with researchers from Sorbonne University in Paris, France, and the University of São Paulo in Brazil,

Honors

Notable publications

References

  1. 1 2 Azvolinsky, Anna (April 1, 2019). "Cancer Vaxxer: A Profile of Miriam Merad". the-scientist.com. Retrieved June 15, 2025.
  2. "Three Scientists to Receive Top Honors from the Cancer Research Institute for Outstanding Contributions to Cancer Immunology and Immunotherapy". cancerresearch.org. Cancer Research Institute. Retrieved 31 May 2019.
  3. "2020 NAS Election". www.nasonline.org. Retrieved 28 April 2020.
  4. "National Academy of Medicine Elects 100 New Members". www.nam.edu/. 9 October 2023. Retrieved 11 October 2023.
  5. "miriam-merad, MD, PhD". icahn.mssm.edu. Retrieved 3 June 2019.
  6. "Engleman Trainees 1983-present" (PDF). Retrieved 3 June 2019.
  7. "Irving L. Weissman, MD" . Retrieved 6 Dec 2022.
  8. "miriam-merad, MD/PhD". icahn.mssm.edu. Retrieved 3 June 2019.
  9. "Human Immune Monitoring Center". www.mountsinai.org/. Retrieved 15 Dec 2022.
  10. "Microbiome Translational Center". www.mountsinai.org/. Retrieved 15 Dec 2022.
  11. "Center for Inborn Errors of Immunity". www.mountsinai.org/. Retrieved 15 Dec 2022.
  12. "Finding Common Cause to Advance Immunotherapy Access with Novel Programs". www.mountsinai.org/. Retrieved 15 Dec 2022.
  13. "The Tisch Cancer Institute and Precision Immunology Institute at Mount Sinai Launch Center for Computational Immunology". www.mountsinai.org/. Retrieved 15 Dec 2022.
  14. "Icahn School of Medicine at Mount Sinai Names Miriam Merad, MD, PhD, as Dean for Translational Research and Therapeutic Innovation". www.newswise.com. Retrieved 2024-04-30.
  15. Hashimoto, Daigo; Chow, Andrew; Noizat, Clara; Teo, Pearline; Beasley, Mary Beth; Leboeuf, Marylene; Becker, Christian D.; See, Peter; Price, Jeremy; Lucas, Daniel; Greter, Melanie; Mortha, Arthur; Boyer, Scott W.; Forsberg, E. Camilla; Tanaka, Masato; Van Rooijen, Nico; García-Sastre, Adolfo; Stanley, E. Richard; Ginhoux, Florent; Frenette, Paul S.; Merad, Miriam (2013). "Tissue-Resident Macrophages Self-Maintain Locally throughout Adult Life with Minimal Contribution from Circulating Monocytes". Immunity. 38 (4): 792–804. doi:10.1016/j.immuni.2013.04.004. PMC   3853406 . PMID   23601688.
  16. Ginhoux, Florent; Greter, Melanie; Leboeuf, Marylene; Nandi, Sayan; See, Peter; Gokhan, Solen; Mehler, Mark F.; Conway, Simon J.; Ng, Lai Guan; Stanley, E. Richard; Samokhvalov, Igor M.; Merad, Miriam (2010). "Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages". Science. 330 (6005): 841–845. Bibcode:2010Sci...330..841G. doi:10.1126/science.1194637. PMC   3719181 . PMID   20966214.
  17. Ginhoux, Florent; Collin, Matthew P.; Bogunovic, Milena; Abel, Michal; Leboeuf, Marylene; Helft, Julie; Ochando, Jordi; Kissenpfennig, Adrien; Malissen, Bernard; Grisotto, Marcos; Snoeck, Hans; Randolph, Gwendalyn; Merad, Miriam (2007). "Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state". The Journal of Experimental Medicine. 204 (13): 3133–3146. doi:10.1084/jem.20071733. PMC   2150983 . PMID   18086862 . Retrieved 11 May 2022.
  18. Bigenwald, Camille; Le Berichel, Jessica; Wilk, C. Matthias; Chakraborty, Rikhia; Chen, Steven T.; Tabachnikova, Alexandra; Mancusi, Rebecca; Abhyankar, Harshal; Casanova-Acebes, Maria; Laface, Ilaria; Akturk, Guray; Jobson, Jenielle; Karoulia, Zoi; Martin, Jerome C.; Grout, John; Rafiei, Anahita; Lin, Howard; Manz, Markus G.; Baccarini, Alessia; Poulikakos, Poulikos I.; Brown, Brian D.; Gnjatic, Sacha; Lujambio, Amaia; McClain, Kenneth L.; Picarsic, Jennifer; Allen, Carl E.; Merad, Miriam (2021). "BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology". Nature Medicine. 27 (5): 851–861. doi:10.1038/s41591-021-01304-x. PMC   9295868 . PMID   33958797.
  19. Chen, Steven T.; et al. (2022). "A shift in lung macrophage composition is associated with COVID-19 severity and recovery". Science Translational Medicine. 14 (662) eabn5168. doi:10.1126/scitranslmed.abn5168. PMC   10117220 . PMID   36103512.
  20. Casanova-Acebes, María; Dalla, Erica; Leader, Andrew M.; Leberichel, Jessica; Nikolic, Jovan; Morales, Blanca M.; Brown, Markus; Chang, Christie; Troncoso, Leanna; Chen, Steven T.; Sastre-Perona, Ana; Park, Matthew D.; Tabachnikova, Alexandra; Dhainaut, Maxime; Hamon, Pauline; Maier, Barbara; Sawai, Catherine M.; Agulló-Pascual, Esperanza; Schober, Markus; Brown, Brian D.; Reizis, Boris; Marron, Thomas; Kenigsberg, Ephraim; Moussion, Christine; Benaroch, Philippe; Aguirre-Ghiso, Julio A.; Merad, Miriam (2021). "Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells". Nature. 595 (7868): 578–584. Bibcode:2021Natur.595..578C. doi:10.1038/s41586-021-03651-8. PMC   8923521 . PMID   34135508.
  21. Park, Matthew D.; et al. (2023). "TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer". Nature Immunology. 24 (5): 792–801. doi:10.1038/s41590-023-01475-4. PMC   11088947 . PMID   37081148.
  22. Maier, Barbara; Leader, Andrew M.; Chen, Steven T.; Tung, Navpreet; Chang, Christie; Leberichel, Jessica; Chudnovskiy, Aleksey; Maskey, Shrisha; Walker, Laura; Finnigan, John P.; Kirkling, Margaret E.; Reizis, Boris; Ghosh, Sourav; d'Amore, Natalie Roy; Bhardwaj, Nina; Rothlin, Carla V.; Wolf, Andrea; Flores, Raja; Marron, Thomas; Rahman, Adeeb H.; Kenigsberg, Ephraim; Brown, Brian D.; Merad, Miriam (2020). "A conserved dendritic-cell regulatory program limits antitumour immunity". Nature. 580 (7802): 257–262. Bibcode:2020Natur.580..257M. doi:10.1038/s41586-020-2134-y. PMC   7787191 . PMID   32269339.
  23. Magen, Assaf; et al. (2023). "Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma". Nature Medicine. 29 (6): 1389–1399. doi:10.1038/s41591-023-02345-0. PMC   11027932 . PMID   37322116.
  24. Park, Matthew D.; et al. (2024). "Hematopoietic aging promotes cancer by fueling IL-1⍺–driven emergency myelopoiesis". Science. 386 (6720) eadn0327. Bibcode:2024Sci...386n0327P. doi:10.1126/science.adn0327. PMC   7616710 . PMID   39236155.
  25. "Mount Sinai Researchers in Semifinals of $101 Million XPRIZE Healthspan, a Competition Seeking Innovative Approaches to Aging Well". www.globenewswire.com/ (Press release). 12 May 2025. Retrieved 2025-09-04.
  26. Park, Matthew D.; Yatim, Nader; Zhang, Jing; Cho, Byuri Angela; Yoo, Seong-Keun; Schaefer, Maximilian M.; Chowell, Diego; Puleston, Daniel J.; Merad, Miriam (2025). "Restoring resident tissue macrophages to combat aging and cancer". Nature Aging. 5 (8): 1383–1392. doi:10.1038/s43587-025-00898-y. PMID   40813807 . Retrieved 4 September 2025.
  27. Marron, Thomas U.; Galsky, Matthew D.; Taouli, Bachir; Fiel, Maria Isabel; Ward, Stephen; Kim, Edward; Yankelevitz, David; Doroshow, Deborah; Guttman-Yassky, Emma; Ungar, Benjamin; Mehandru, Saurabh; Golas, Benjamin J.; Labow, Daniel; Sfakianos, John; Nair, Sujit S.; Chakravarty, Dimple; Buckstein, Michael; Song, Xiaoyu; Kenigsberg, Effi; Gnjatic, Sacha; Brown, Brian D.; Sparano, Joseph; Tewari, Ashutosh; Schwartz, Myron; Bhardwaj, Nina; Merad, Miriam (2022). "Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery". Nature Medicine. 28 (4): 626–629. doi:10.1038/s41591-022-01681-x. PMC   9901535 . PMID   35347282.
  28. Mehandru, Saurabh; Merad, Miriam (2022). "Pathological sequelae of long-haul COVID". Nature Immunology. 23 (2): 194–202. doi:10.1038/s41590-021-01104-y. PMC   9127978 . PMID   35105985.
  29. Brown, Brian D.; Leader, Andrew M.; Vilcek, Jan; Merad, Miriam (2020). ""America First" Will Destroy U.S. Science". Cell. 183 (4): 841–844. doi:10.1016/j.cell.2020.09.025 . Retrieved 12 May 2022.
  30. Merad, Miriam (2020). "Reflections from a mother scientist". Nature Medicine. 26 (9): 1316. doi:10.1038/s41591-020-1052-8. PMID   32839622 . Retrieved 12 May 2022.
  31. Vabret, Nicolas; Mateus-Tique, Jaime; Salmon, Hélène; Martin, Jérôme C.; Mateo, Véronique; Serrano, Sandra; Lemoine, François; Chammas, Roger; Merad, Miriam (2024). "Online immunology education for a global world". Nature Reviews Immunology. 24: 615–616. doi:10.1038/s41577-024-01066-w. PMID   38997523 . Retrieved 4 September 2025.
  32. "Miriam Merad, MD, PhD, Awarded French Knighthood for Pioneering Contributions to Science and Medicine" . Retrieved 4 September 2025.
  33. "Sjöberg Laureate discovered new targets for cancer therapies in the immune system". YouTube . 12 February 2025. Retrieved 13 February 2025.
  34. "CLASS OF 2025" . Retrieved 10 February 2025.
  35. "Class of 2024" . Retrieved 10 February 2025.
  36. "Global Reach: Inserm Celebrates in Washington, DC, 60 Years of Research and Innovation". 25 October 2024. Retrieved 10 February 2025.
  37. "Les lauréats des Prix Fondation ARC Léopold Griffuel" . Retrieved 10 February 2025.
  38. "About the Academy of Immuno-Oncology" . Retrieved 15 September 2023.
  39. "International Union of Immunological Societies" . Retrieved 20 February 2020.
  40. "The American Society for Clinical Investigation" . Retrieved 3 June 2019.
  41. "Three Scientists to Receive Top Honors from the Cancer Research Institute for Outstanding Contributions to Cancer Immunology and Immunotherapy". cancerresearch.org. Cancer Research Institute. Retrieved 31 May 2019.
  42. "Miriam Merad". www.nasonline.org/. Retrieved 12 May 2022.
  43. "Highly Cited Researchers". www.clarivate.com/. Retrieved 6 May 2022.
  44. "Miriam Merad". Carnegie Corporation of New York. Retrieved June 25, 2024.